EVG.L Regulatory News (EVG)

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

Appoints Chief Medical Officer

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce the appointment of Dr Hamina J Patel MB BCh MSc MRCPI as Chief Medical Officer.

Dr Patel is a pharmaceutical executive with more than 15 years' industry experience, leading global cross functional teams in the development and commercialisation of drugs primarily within the field of oncology.

Dr Patel was previously Director of Drug Development, Oncology, at Johnson and Johnson, where she helped to build a broad and differentiated portfolio of indications for the cancer drug VELCADE® and was instrumental in the success of a new indication (the second-line treatment of mantle cell lymphoma) based on a Phase II clinical study in more than 35 countries. She received numerous awards for her contribution to the Oncology group at Johnson and Johnson, including a Standard of Leadership award.

In addition to her small molecule expertise, Dr Patel has worked extensively in the development of biopharmaceuticals at Celltech and at Chugai.

Dr Patel qualified as a physician in 1990 and worked for almost ten years in hospitals around the UK before moving into the pharmaceutical industry.

Dr Stephen Franklin, Evgen Pharma's CEO, commented: "We are delighted to announce the appointment of Dr Hamina Patel as Evgen's Chief Medical Officer. Hamina has an impressive track record at global pharmaceutical companies and a breadth of relevant clinical experience. Her appointment strengthens the core team at Evgen and will be of great value in the delivery of our upcoming Phase II clinical trials in metastatic breast cancer and in subarachnoid haemorrhage, both of which are on track to begin this year."

Enquiries:

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.  For further information please visit www.evgen.com